GlassScriptPhysician profile
Sean T Mullendore
NPI 1821081365
$4,647.90
in general payments reported to CMS, 2019-2025
41 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 90% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $270 · 2021: $351 · 2022: $534 · 2023: $890 · 2024: $798 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,777.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.99 | 2019-2025 | |
| Novo Nordisk INC | $774.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $607.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $368.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $331.87 | 2019-2025 | Airsupra, Breztri, Bydureon |
| Bayer Healthcare Pharmaceuticals INC. | $261.33 | 2022-2025 | |
| Amgen INC. | $121.06 | 2019-2025 | Evenity, Prolia |
| Myriad Women'S Health, INC. | $111.78 | 2023 | Myrisk |
| Takeda Pharmaceuticals U.S.A., INC. | $100.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.86 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $80.05 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $77.76 | 2022-2025 | Veozah |
| Gilead Sciences, INC. | $71.11 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $69.57 | 2021-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.93 | 2025 | Caplyta |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Mullendore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.